Main Article Content

Abstract

The main objective of present study is to formulate and evaluate oral in situ gel of the Glimepiride. The oral in situ gelling formulations were prepared using Sodium alginate, HPMC K15M, Calcium carbonate and Methyl paraben. Glimepiride is an antidiabetic and antiarrhythmia agents of the third generation sulfonyl urea’s derivative family. Glimepiride has half-life 58 hours and required dose is 1-6 mg a day. It is used for the treatment of Type-2 Diabetes, which acts to trigger pancreas to make more insulin. This may account for better safety profile of drug. The formulation was studied for FT-IR study to interpret the interaction between Drug-Polymer used. Prepared formulations were evaluated for Clarity, PH measurement, Homogeneity, Spreadability, Viscosity measurement, Drug content, Extrudability and Drug diffusion studies. An In vitro drug release study was compared among the different in situ gelling formulations and F3 released 96.8% of drug at the end of 12th hour and was considered as a best formulation. The release of drug through these in situ gel formulations followed by the different kinetic models shows non-fickian diffusion (n=0.576) which was best explained by peppas kinetic model. The formulation F3 was found to be stable for 3 months in accelerated stability study.

Keywords

Type 2 Diabetes Glimepiride Oral in situ gel In vitro drug release Drug release kinetics etc

Article Details

How to Cite
P, V., Syed Moula ali, Ramesh, Y., & K, S. (2017). FORMULATION AND EVALUATION OF ORAL In-Situ GEL OF GLIMEPIRIDE . International Journal of Pharmacometrics and Integrated Biosciences, 2(2), 50-55. Retrieved from https://scienztech.org/index.php/ijpib/article/view/950